{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:34:28Z","timestamp":1787506468743,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004637","name":"Nanchang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.eprac.2024.11.007","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T03:37:20Z","timestamp":1731987440000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive Analysis of Mitotane-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-518X","authenticated-orcid":false,"given":"Xing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.11.007_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101415","article-title":"New perspectives for mitotane treatment of adrenocortical carcinoma","volume":"34","author":"Puglisi","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.eprac.2024.11.007_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.eprac.2024.11.007_bib3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s11864-024-01249-6","article-title":"Systemic management of advanced adrenocortical carcinoma","volume":"25","author":"Russell","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.eprac.2024.11.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111243","article-title":"Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells","volume":"528","author":"Maria","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.007_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/oncolo\/oyae084","article-title":"A\u00a0review of mitotane in the management of adrenocortical cancer","volume":"29","author":"Del Rivero","year":"2024","journal-title":"Oncol"},{"key":"10.1016\/j.eprac.2024.11.007_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(53)90992-1","article-title":"D.D.D. therapy in Cushing's syndrome","volume":"1","author":"Sheehan","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.11.007_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s002800050610","article-title":"Adrenal proteins bound by a reactive intermediate of mitotane","volume":"39","author":"Cai","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eprac.2024.11.007_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14656566.2022.2106128","article-title":"Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?","volume":"23","author":"Cremaschi","year":"2022","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.eprac.2024.11.007_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.952418","article-title":"Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series","volume":"13","author":"T\u0151ke","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.007_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1259628","article-title":"The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eprac.2024.11.007_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/jdv.19703","article-title":"Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system","volume":"38","author":"Jedlowski","year":"2024","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eprac.2024.11.007_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1266890","article-title":"Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eprac.2024.11.007_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.eprac.2024.11.007_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.eprac.2024.11.007_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A\u00a0real-world disproportionality analysis of Olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.eprac.2024.11.007_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/amiajnl-2012-001119","article-title":"Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records","volume":"20","author":"Liu","year":"2013","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.eprac.2024.11.007_bib17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/cancers12030639","article-title":"Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma","volume":"12","author":"Poirier","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.eprac.2024.11.007_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.007_bib19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.1992.10.9.1504","article-title":"Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms","volume":"10","author":"Lanser","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.11.007_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1222002","article-title":"Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study","volume":"13","author":"Mormando","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eprac.2024.11.007_bib21","doi-asserted-by":"crossref","first-page":"G15","DOI":"10.1093\/ejendo\/lvae038","article-title":"International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects","volume":"190","author":"Riedmeier","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.007_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.007_bib23","first-page":"911","article-title":"No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma","volume":"35","author":"Ederhy","year":"2012","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.eprac.2024.11.007_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.11.007_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/EJE-14-0670","article-title":"Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing\u2019s disease","volume":"172","author":"Salenave","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.007_bib26","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cancers12092615","article-title":"Unwanted hormonal and metabolic effects of Postoperative adjuvant mitotane treatment for adrenocortical cancer","volume":"12","author":"Basile","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.007_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0032-1327579","article-title":"Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial","volume":"224","author":"Redlich","year":"2012","journal-title":"Klin Padiatr"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:49:49Z","timestamp":1741009789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1530891X24008322"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Analysis of Mitotane-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}